乙型肝炎相关性肝癌抗病毒治疗研究进展

Research progress of antiviral therapy for hepatitis B-associated hepatocellular carcinoma

原发性肝癌恶性程度高,预后较差。肝细胞癌(HCC)作为原发性肝癌的主要组成部分,其发生与众多因素有关,在中国主要是乙型肝炎病毒(HBV)感染。精准肝脏外科治疗的推广使中国HCC患者获益良多,但近年来死亡率并未明显下降,而导致其结果的根本原因在于治疗过程中未能有效抑制病毒复制。目前,国内外已有多项研究证实,抗病毒治疗能够有效预防HBV再激活,减轻肝功能损伤,减少肿瘤复发和转移,延长患者的总生存期和无病生存期。本文将概述国内外HBV相关性HCC抗病毒治疗的最新研究进展,讨论其临床应用价值。

Primary liver cancer is highly malignant and has a poor prognosis.Hepatocellular carcinoma(HCC),as a major component of primary liver cancer,is associated with numerous factors,mainly hepatitis B virus(HBV)infection in China.The promotion of precision liver surgery has benefited HCC patients in China,but the mortality rate has not decreased significantly in recent years.The fundamental reason for this outcome is the failure to effectively inhibit viral replication during the treatment process.Currently,several studies at home and abroad have confirmed that antiviral therapy can effectively prevent HBV reactivation,reduce liver function injury,decrease tumor recurrence and metastasis,and prolong patients'overall survival(OS)and disease-free survival(DFS).This review outlined the latest research progress of antiviral therapy for HBV-associated HCC at home and abroad,and discussed its clinical application value.